1. In Vivo
  2. >>Business Strategy

bioMerieux-Pierre Fabre Lives Up to Its Name

Only seven weeks after merging, French diagnostic-pharma company bioMerieux-Pierre Fabre is proposing to buy Organon Teknika's diagnostics business. The deal would combine two players with complementary, not overlapping, strengths in microbiology and infectious diseases. Under Dutch labor law, the proposal must be reviewed by Dutch employee groups and antitrust regulators before Organon Teknika's parent, Akzo Nobel NV, can formally accept it.

It hasn't taken bioMerieux-Pierre Fabre SAlong to act. Founders Alain Merieux and Pierre Fabre insisted when they agreed to merge their companies last fall that one of the key attractions would be to bolster bioMerieux's position in diagnostics and Pierre Fabre's in pharmaceuticals (see bioMerieux's and Pierre Fabre's Surprise, IN VIVO, October 2000 [A#2000800180 [See Deal]); in rapidly consolidating industries, both French companies were simply too small to be effective. Now, two months after the deal closed, the new company is proposing to pay $322 million for the clinical diagnostics businesses of Organon Teknika NV, the health care unit of Dutch conglomerate Akzo Nobel NV —roughly 1 1/4 times Organon's clinical diagnostics sales of $250 million.

The deal would combine two players with strong interests in microbiology and infectious disease testing—albeit with different strengths in each....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.